TR 004

Drug Profile

TR 004

Alternative Names: TR-004; Treg immunotherapy

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Miltenyi Biotec GmbH
  • Class Cell therapies; Immunotherapies; Regulatory T lymphocyte cell therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Crohn's disease

Most Recent Events

  • 13 Apr 2017 Miltenyl Biotech, in collaboration with Kings College London, plans the phase I/II TRIBUTE trial for Crohn's disease (In adults, In the elderly) in February 2018 (NCT03185000)
  • 13 Apr 2017 Preclinical trials in Crohn's disease in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top